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rug-Specific or Class Effect?*
orin J. Brener, MD
rooklyn, New York
or patients with ST-segment elevation (acute) myocardial
nfarction (STEMI), reperfusion with primary percutaneous
oronary intervention (PCI) results in excellent short- and
ong-term outcome, predominantly because of the high rate
f restoration of normal flow at the epicardial and myocar-
ial levels (1). Despite its success, primary PCI remains
raught with obstacles because of the high thrombus burden,
ifficulty in initial assessment of lesion length and vessel
ize, and consequences of distal embolization of plaque and
hrombus. Thus, adjunctive pharmacology has always been
n important tool for addressing these challenges. Oral and
ntravenous platelet inhibitors and intravenous thrombin
nhibitors have been used in various combinations to reduce
hrombus size and prevent its reaccumulation after success-
ul reperfusion.
See page 1668
After their introduction 2 decades ago, intravenous an-
agonists of the platelet glycoprotein IIb/IIIa (GPIs) (2)
eceptor quickly became the most researched intervention in
ardiology, with numerous studies performed in a variety of
linical scenarios, ranging from adjunctive therapy to PCI in
table patients to primary PCI for STEMI (3,4). Tens of
housands of patients with varying clinical profile and acuity
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.r
From the New York Methodist Hospital, Department of Cardiology, Brooklyn,
ew York.ave been enrolled in pre- and post-marketing studies of
PIs. The prototypical agent, abciximab, is a large, chi-
eric antibody to the glycoprotein (GP) receptor, which
terically hinders its binding to fibrinogen in a nearly
rreversible fashion, preventing platelet aggregation and
otentially promoting deaggregation of recently formed
latelet-rich thrombi, as occurs in STEMI (5,6). Initially,
here was considerable enthusiasm about the “pleiotropic”
ffects of abciximab, such as inhibition of the vitronectin
eceptor and prevention of white blood cells aggregation to
latelets and to the vascular wall (7). These interactions
ere hypothesized to lead to less restenosis and inflamma-
ion after PCI. Subsequent laboratory work resulted in the
ynthesis of smaller, cheaper molecules (peptides and non-
eptides), which bind specifically and reversibly to the
eceptor and allow for quicker recovery of platelet function
fter discontinuation of infusion. As compared with abcix-
mab’s long clearance time of 12 to 24 h, these small
olecules had a clearance time of only 2 to 2.5 h, making
hem particularly attractive when urgent reversal of their
ffect was desirable. When administered in a dose sufficient
o inhibit platelet aggregation by at least 80%, these com-
ounds proved equally able as abciximab to inhibit shedding
f soluble CD40 ligand, a compound associated with
ncreased inflammation and restenosis after PCI (8).
The use of abciximab in STEMI was first studied more
han 10 years ago in the RAPPORT (ReoPro and Primary
TCA Organization and Randomized) trial (9). Compared
ith placebo, abciximab reduced the incidence of death,
einfarction, or urgent revascularization at 7 days (11.2% vs.
.8%, respectively, p  0.03), but had no effect on late,
onurgent repeat revascularization. The 30-day death (2.1%
s. 2.5%) and reinfarction (4.1% vs. 3.3%) rates were similar
etween the groups. Earlier administration of the drug, even
efore angiography, seemed to result in the best outcome, in
randomized study and in a large registry. With the
xception of 1 small study comparing eptifibatide with
lacebo (10), most of the STEMI experience has been
ccumulated with abciximab.
In this issue of the Journal, De Luca et al. (11) summarize
he results of 6 trials comparing the outcome of primary
CI in 2,197 patients treated with abciximab, high-dose
irofiban, or eptifibatide between 2002 and 2007. In 5
tudies, abciximab was compared with high-dose tirofiban
dosing regimen not approved by the Food and Drug
dministration), and in 1, eptifibatide was pitted against
bciximab. At 30 days death occurred in 2.2% of abciximab
atients and 2.0% of tirofiban or eptifibatide patients (p 
.66) and reinfarction occurred in 1.2% in each group (p 
.88), without heterogeneity among the trials or evidence
or publication bias. Furthermore, there was no evidence for
uperiority of either type of drug with respect to angio-
raphic (restoration of Thrombolysis In Myocardial Infarc-
ion flow grade 3) or electrocardiographic (ST-segment
esolution) parameters, which occurred in a high proportion
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May 5, 2009:1674–6 GP Receptor Inhibitors in STEMIf the patients. Major bleeding was low and comparable
mong the 2 groups. The authors elegantly discuss the
mplications of their findings and recognize that their study
s significantly underpowered to detect even a 1% absolute
eduction in mortality between the groups, the difference
bserved between lytic regimens in a landmark reperfusion
tudy.
Currently, in the American College of Cardiology/
merican Heart Association guidelines abciximab use as
djunct to primary PCI carries a Class IIA (Level of
vidence: B) recommendation, while the small molecules
eceived a Class IIB (Level of Evidence: C) recommenda-
ion (12). Are the guidelines correct? How should one
nterpret these results?
Using the data shown in Table 1, we can conclude that
PIs in general, and abciximab in particular (the others
ave not been extensively studied), are superior to placebo in
mproving the outcome of primary PCI. The benefit is small
n absolute terms, particularly when the patients studied are
elatively low-risk and cardiogenic shock is excluded. Mor-
ality can be reduced more significantly in higher-risk
atients, as shown in 1 study (13). The effect on myocardial
nfarction is most obvious in patients receiving percutaneous
ransluminal coronary angioplasty only, who are at higher
isk of abrupt vessel closure soon after the procedure.
espite the putative advantages of abciximab with respect
o inhibition of additional proinflammatory pathways, the
mall molecules appear to do as well as abciximab as far as
schemic events are concerned and the less enthusiastic
ecommendation for their use stems from a lack of compar-
tive data to placebo. Finally, it is possible that on the
ackground of aspirin and thienopyridine, the use of GPIs
an be replaced completely with bivalirudin without any
isadvantage in prevention of ischemic events (14).
Ultimately, when the mortality is as low as that observed
n contemporary randomized clinical trials of primary PCI,
t is very difficult to demonstrate added benefit from one
ntervention, particularly when it is compared with another
ith similar effect. Mortality cannot be completely elimi-
ated in STEMI patients. The lack of statistical power of
ecent Studies and Meta-Analysesf R perfusion With Primary PCI for STEMI
Table 1 Recent Studies and Meta-Analysesof Reperfusion With Primary PCI for STEMI
De Luca et al.
2005* (17)
De Luca et al.
2009† (11)
Stone et al.
2008‡ (14)
n 3,949 2,197 3,602
Period 1995–2002 2002–2007 2005–2007
30-day death 2.4% vs. 3.4% 2.2% vs. 2.0% 2.1% vs. 3.1%
Change vs. control therapy 29%§ 10% 30%§
30-day MI 1.0% vs. 1.9% 1.2% vs. 1.2% 1.8% vs. 1.8%
Change vs. control therapy 47%§ 0% 0%
Meta-analysis (8 studies) of abciximab versus placebo; †meta-analysis (6 studies) of abciximab
ersus small-molecule glycoprotein IIb/IIIa inhibitors; ‡randomization to bivalirudin versus abcix-
mab or small-molecule glycoprotein IIb/IIIa inhibitors; §signifies p  0.05.
MI  myocardial infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment
levation myocardial infarction.he current meta-analysis underscores this concept. It isnlikely, in the current era of primary PCI, that additional
tudies, large enough to detect small differences in rare
vents, will be performed. The use of surrogate end points,
uch as extent of angiographic or electrocardiographic
eperfusion, is not likely to overcome this fact, even if
ifferences between compounds were found.
The information we currently possess is sufficient to guide
ur practice in that GPIs are likely to improve outcome,
ompared with placebo or control therapy, particularly in
igh-risk STEMI patients, receiving the drug as early as
ossible after diagnosis and before primary PCI (15–17).
he choice of GPI is more dependent on cost and consid-
rations of reversibility rather than on efficacy, as long as
rugs with similar ability to inhibit platelet aggregation are
iven. STEMI is probably the last segment of the PCI
opulation for which GPI has a defined role, until addi-
ional studies with alternative antithrombotic regimens are
erformed.
eprint requests and correspondence: Dr. Sorin J. Brener, New
ork Methodist Hospital, Department of Cardiology, 506 6th
treet, Brooklyn, New York 11215. E-mail: sjb9005@nyp.org.
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